Additional file 8 of N6-methyladenosine-modified circIGF2BP3 inhibits CD8+ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer

Additional file 8: Figure S8. PKP3/PD-L1 axis inhibition enhances the efficacy of anti-PD-1 therapy. A. Schematic diagram showing the grouping and treatment plan of the in vivo study: PD-L1 WT or PD-L1 KO mice were inoculated with sh-mouse PKP3 LLC cells, and the tumor volume was measured at the indicated time points. B. Left panel: FACS histogram showing PD-L1 levels on myeloid cells (CD11b+) from PD-L1 KO or WT mice. Right panel: FACS histogram showing PD-L1 levels in LLC cells with or without mouse PKP3 silencing. C. Time-course evaluation of tumor volumes of each group measured every 3 days. D. Quantification of the flow cytometry data demonstrating the percentage of CD3+ cells among CD45+ T cells; CD8+ T cells among CD3+ cells; and GZMB+ T cells among CD8+ cells. E. Schematic diagram showing the grouping and treatment plan of the in vivo study: C57BL/6 mice were inoculated with 106 CTRL, PKP3-OE, or circIGF2BP3-OE LLC cells with or without anti-PD-1 treatment, and the tumor volume was measured at the indicated time points. F. Left panel: PD-L1 expression in implanted LLC cells of each group was analyzed by FACS. Right panel: PD-L1 expression in CD45+ cells isolated from tumor tissues of each group was analyzed by FACS. G. Time-course evaluation of tumor volumes of each group measured every 3 days. H. Quantification of the flow cytometry data demonstrating the percentage of CD3+ cells among CD45+ T cells; CD8+ T cells among CD3+ cells; and GZMB+ T cells among CD8+ cells. Data represent the mean ± SD. P values were by one-way ANOVA with Tukey’s post hoc test